The effect of PPAR ligands to modulate glucose metabolism alters the incorporation of metabolic precursors into proteoglycans synthesized by human vascular smooth muscle cells

References

• Calabro A, Benavides M, Tammi M, Hascall V C, Midura R J. Microanalysis of enzyme digests of hyaluronan and chondroitin/dermatan sulphate by fluorophore-assisted carbohydrate electrophoresis (FACE). Glycobiology 2000a; 10: 273–281
   PubMed Web of Science ®Google Scholar
• Calabro A, Hascall V C, Midura R J. Adaptation of FACE methodology for microanalysis of total hyaluronan and chondroitin sulphate composition from cartilage. Glycobiology 2000b; 10: 283–293
   PubMed Web of Science ®Google Scholar
• Calkin A C, Forbes J M, Smith C M, Lassila M, Cooper M E, Jandeleit-Dahm K A, Allen T J. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 2005; 25: 1903–1909
   PubMed Web of Science ®Google Scholar
• Collins A R, Meehan W P, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh W A, Law R E. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 365–371
   PubMed Web of Science ®Google Scholar
• de Dios S T, Bruemmer D, Dilley R J, Ivey M E, Jennings G L, Law R E, Little P J. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003; 107: 2548–2550
   PubMed Web of Science ®Google Scholar
• de Dios S T, Frontanilla K V, Nigro J, Ballinger M L, Ivey M E, Cawson E A, Little P J. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. J Diabetes Complications 2007; 21: 108–117
   PubMed Web of Science ®Google Scholar
• Diamond G A, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147: 578–581
   PubMed Web of Science ®Google Scholar
• Dormandy J A, Charbonnel B, Eckland D J, Erdmann E, Massi-Benedetti M, Moules I K, Skene A M, Tan M H, Lefebvre P J, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–1289
   PubMed Web of Science ®Google Scholar
• Duez H, Chao Y S, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton C A, Tedgui A, et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 2002; 277: 48051–48057
   PubMed Web of Science ®Google Scholar
• Fruchart J C, Staels B, Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol Res 2001; 44: 345–352
   PubMed Web of Science ®Google Scholar
• Gustafsson M, Boren J. Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol 2004; 15: 505–514
   PubMed Web of Science ®Google Scholar
• Home P D, Pocock S J, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones N P. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia 2005; 48: 1726–1735
   PubMed Web of Science ®Google Scholar
• Jarvelainen H T, Kinsella M G, Wight T N, Sandell L J. Differential expression of small chondroitin/dermatan sulphate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem 1991; 266: 23274–23281
   PubMed Web of Science ®Google Scholar
• Keech A, Simes R J, Barter P, Best J, Scott R, Taskinen M R, Forder P, Pillai A, Davis T, Glasziou P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849–1861
   PubMed Web of Science ®Google Scholar
• Kihara S, Ouchi N, Funahashi T, Shinohara E, Tamura R, Yamashita S, Matsuzawa Y. Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. Atherosclerosis 1998; 136: 163–168
   PubMed Web of Science ®Google Scholar
• Komers R, Vrana A. Thiazolidinediones – tools for the research of metabolic syndrome X. Physiol Res 1998; 47: 215–225
   PubMed Web of Science ®Google Scholar
• Little P J, Ballinger M L, Osman N. Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. Vascular Health Risk Management 2007a; 3: 1–8
   PubMedGoogle Scholar
• Little P J, Osman N, de Dios S T, Cemerlang N, Ballinger M, Nigro J. Anti-proliferative activity of oral anti hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions. Cardiovasc Diabetol 2007b; 6: 33
   PubMedGoogle Scholar
• Nakashima Y, Fujii H, Sumiyoshi S, Wight T N, Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 2007; 27: 1159–1165
   PubMed Web of Science ®Google Scholar
• Neve B P, Fruchart J, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000; 60: 1245–1250
   PubMed Web of Science ®Google Scholar
• Neylon C B, Little P J, Cragoe E J, Jr, Bobik A. Intracellular pH in human arterial smooth muscle. Regulation by Na+/H+ exchange and a novel 5-(N-ethyl-N-isopropyl)amiloride-sensitive Na(+)- and HCO3(–)-dependent mechanism. Circ Res 1990; 67: 814–825
   PubMed Web of Science ®Google Scholar
• Nigro J, Ballinger M, Dilley R, Jennings G, Wight T, Little P. Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces LDL binding. Diabetologia 2004; 47: 2105–2113
   PubMed Web of Science ®Google Scholar
• Nigro J, Ballinger M L, Osman N, Dart A M, Little P J. Anti-atherogenic role of peroxisome proliferator activated receptor ligands. Current Cardiology Reviews 2005; 1: 89–102
   Google Scholar
• Nigro J, Dilley R J, Little P J. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis 2002; 162: 119–129
   PubMed Web of Science ®Google Scholar
• Nissen S E, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471
   PubMed Web of Science ®Google Scholar
• Plutzky J. Medicine. PPARs as therapeutic targets: reverse cardiology? Science 2003; 302: 406–407
   Google Scholar
• Salustri A, Yanagishita M, Hascall V C. Synthesis and accumulation of hyaluronic acid and proteoglycans in the mouse cumulus cell-oocyte complex during follicle-stimulating hormone-induced mucification. J Biol Chem 1989; 264: 13840–13847
   PubMed Web of Science ®Google Scholar
• Scatena R, Bottoni P, Martorana G E, Ferrari F, De Sole P, Rossi C, Giardina B. Mitochondrial respiratory chain dysfunction, a non–receptor–mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. Biochem Biophys Res Commun 2004; 319: 967–973
   PubMed Web of Science ®Google Scholar
• Schonherr E, Jarvelainen H T, Sandell L J, Wight T N. Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulphate proteoglycan by arterial smooth muscle cells. J Biol Chem 1991; 266: 17640–17647
   PubMed Web of Science ®Google Scholar
• Tannock L R, Little P J, Tsoi C, Barrett P HR, Wight T N, Chait A. Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia 2004; 47: 837–843
   PubMed Web of Science ®Google Scholar
• Williams K J, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551–561
   PubMed Web of Science ®Google Scholar
• Yanagishita M, Salustri A, Hascall V C. Specific activity of radiolabeled hexosamines in metabolic labeling experiments. Methods Enzymol 1989; 179: 435–445
   PubMed Web of Science ®Google Scholar
• Yao L Y, Moody C, Schonherr E, Wight T N, Sandell L J. Identification of the proteoglycan versican in aorta and smooth muscle cells by DNA sequence analysis, in situ hybridization and immunohistochemistry. Matrix Biol 1994; 14: 213–225
   PubMed Web of Science ®Google Scholar
• Yonemitsu S, Nishimura H, Shintani M, Inoue R, Yamamoto Y, Masuzaki H, Ogawa Y, Hosoda K, Inoue G, Hayashi T, Nakao K. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 2001; 50: 1093–1101
   PubMed Web of Science ®Google Scholar